ArticleThe Journal of thoracic and cardiovascular surgery2026
Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer.
Article in The Journal of thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
22 authors.
Funding
Abstract
objectiveNeoadjuvant chemoimmunotherapy has improved outcomes in resectable non-small cell lung cancer, yet its real-world implementation is often challenged by surgical delays, immune-mediated fibrosis, and postoperative complications. Smokers with non-small cell lung cancer, despite a high risk for surgical morbidity, show enhanced responses to neoadjuvant chemoimmunotherapy. This study aimed to identify smoking-associated immune cell determinants that could guide treatment strategies.
methodsSingle-cell RNA sequencing was performed on 61 lung tissues from nonsmokers and smokers to identify smoking-related immune compositions. The single-cell RNA sequencing data from 19 invasive lung adenocarcinomas were used to validate their presence in the tumor-immune microenvironment. Bulk RNA sequencing data from 102 patients with resected non-small cell lung cancer and 24 patients with non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy followed by surgery were used for in silico cellular deconvolution and outcome analyses.
resultsAmong 135 lung cellular phenotypes, 2 natural killer cell subsets were strongly associated with smoking and chronic obstructive pulmonary disease severity. "Stress-responsive" natural killer cells exhibited immature features and cytokine-responsive features, and "adaptive and immunoregulatory natural killer" cells showed mature features and elevated multiple immune checkpoint expression. High intratumoral "stress-responsive" natural killer cells correlated with improved survival after surgery, particularly in current smokers. Conversely, tumors with low "stress-responsive" natural killer and high "adaptive and immunoregulatory natural killer" cells responded more favorably to neoadjuvant chemoimmunotherapy.
conclusionsIntratumoral natural killer cell phenotyping may aid in therapeutic stratification in patients with non-small cell lung cancer. "Stress-responsive" natural killer cell preservation predicts benefit from up-front surgery, whereas "adaptive and immunoregulatory natural killer" cell enrichment indicates improved response to neoadjuvant chemoimmunotherapy. These natural killer cell profiles may help optimize treatment by balancing therapeutic benefit and risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.